img Not actual patient.
LET’S TALK ABOUT

PATIENTS LIKE JASON

A patient with type 2 diabetes struggling to maintain glycemic control

Diagnosed with type 2 diabetes 6 years ago

On daily regimen of multiple oral agents (OAs), weekly GLP 1 injection, and just started using CGM

Has an A1C over 9.0 and wants to achieve glycemic target

Doesn't want to deal with daily mealtime injections

CGM

Helps Jason
identify glucose
excursions

GIVE PATIENTS LIKE JASON IMPROVED MEALTIME CONTROL WITH AFREZZA®1,8

  • Afrezza delivers an ultra-rapid insulin response with absorption in the blood in <1 minute1,4
  • Time to first measurable effect is ~12 minutes1
  • Patients inhale Afrezza at mealtime, when they are ready to eat, with no needlesticks1
  • One out of three patients with type 2 diabetes treated with OAs plus Afrezza achieved
    A1C ≤7% versus OAs alone1
img Not actual patient.
TYPE2

Patient Profile:Jason

Drag & Drop:What features of an inhaled insulin might help a patient like Jason?

Drag the items to sort them in the order of importance to you, with 1 being the most important

Reduction of
A1C levels1,8
Safety profile1
Flexible and convenient dosing1
123
img

Jason’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION WITH

SUPERIOR CONTROL

Adding Afrezza® significantly reduced A1C levels compared to OAs alone1,8

TYPE2

APPROXIMATELY ONE OUT OF THREE PATIENTS ACHIEVED A1C ≤7% WITH AFREZZA1

img
img

Study design:Afrezza efficacy was studied in a 24-week, double-blind, placebo-controlled, international, multicenter phase 3 trial of insulin-naive adults with type 2 diabetes (n=353) uncontrolled (A1C >7%) on optimal/maximally tolerated doses of either metformin alone or 2 or more OAs. Patients were treated with Afrezza plus OAs or inhaled placebo powder without insulin plus OAs.

The primary efficacy endpoint was the average change in A1C from baseline (randomization) to week 24. At week 24, Afrezza plus OAs had an A1C of -0.82%, OAs only had an A1C of -0.42% (P<0.0001).8

img

Jason’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION WITH

SUPERIOR CONTROL

Adding Afrezza® significantly reduced A1C levels compared to OAs alone1,8

TYPE2

GIVE YOUR PATIENTS WITH TYPE 2 DIABETES IMPROVED MEALTIME CONTROL1,8

img

ADDAfrezza to OAs to avoid introducing injections1,8

img

ADDAfrezza to basal insulin to avoid mealtime injections10

img
img

Jason’s
Journey

Your
ranking

LET’S TALK ABOUT

THE SAFETY PROFILE

TYPE2

INCIDENCE OF SEVERE AND NON-SEVERE HYPOGLYCEMIA IN A PLACEBO-CONTROLLED TYPE 2 STUDY1

img

Study design: Afrezza efficacy was studied in a 24-week, randomized, double-blind, placebo-controlled, international, multicenter phase 3 study in insulin-naive adults with t2dm (n=353) uncontrolled (A1C > 7%) on optimal/maximally tolerated doses of either metformin alone
or 2 or more OAs. Patients were treated with Afrezza + OAs or inhaled placebo powder without insilin + OAs.

img

Jason’s
Journey

Your
ranking

LET’S TALK ABOUT

THE SAFETY PROFILE

Afrezza® has been studied in over 3,000 patients with diabetes1

TYPE2

MOST COMMON ADVERSE REACTIONS (EXCLUDING HYPOGLYCEMIA) FROM POOLED
SAFETY RESULTS IN TYPE 2 DIABETES1

img

Common adverse reactions, excluding hypoglycemia, associated with the use of Afrezza in the pool of controlled trials in type 2 diabetes patients. These adverse reactions were not present at baseline, occurred more commonly on Afrezza than on placebo and/or comparator, and occurred in at least 2% of patients treated with Afrezza.1

img

Jason’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION ABOUT

DOSING + TITRATION

Afrezza® mealtime control is possible with flexible dosing1

12 - 24 Units

Typical mealtime dose in clinical trials7,9

1.5x

Suggested conversion from injectable insulin to Afrezza units for comparable effect7,9,10

Adjust Dosing

Example: Increase by 4 units per meal every 3 days until glucose is controlled

This Afrezza Titration Pack offers flexibility for patients getting started:

img

Jason’s
Journey

Your
ranking

LET’S CHANGE THE CONVERSATION ABOUT

DOSING + TITRATION

Afrezza® mealtime control is possible with flexible dosing1

TYPE2

EXAMPLE DOSING FOR PRANDIAL INSULIN NAIVE

4 Afrezza Units
given with each meal for 3 days
(total of 12 Afrezza units per day)

img

Dose for 3 days
Dose adjusted to 8 units with each meal based on 2 hr PPG x 3 days (PPG >160 mg/dL)

Days: 1-3

8 Afrezza Units
given with each meal for 3 days
(total of 24 Afrezza units per day)

img

Titrate up to 3 days
Dose adjusted to 12 units with each meal based on 2 hr PPG x 3 days (PPG >160 mg/dL)

Days: 4-6

12 Afrezza Units
given with each meal for 3 days
(total of 36 Afrezza units per day)

img

Titrate to effect
Dose adjusted to 16 units with each meal based on 2 hr PPG x 3 days (PPG >160 mg/dL)

Days: 7-9
img
Continue to adjust dose by 4-unit increments
every 3 days until PPG is controlled.
REFERENCES
  • Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation.
  • Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled Technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther. 2018;20(10):639–647.
  • Lasalle JR, Berria R. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other health care professionals. J Am Osteopath Assoc. 2013;113(3):152–162.
  • Rave K, Heise T, Heinemann L, et al. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2(2):205–212.
  • Rossetti P, Porcellati F. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(2):S113–S120.
  • Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245.
  • Bode BW, McGill JB, Lorber DL, et al. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38(12):2266–2273.
  • Rosenstock J, Franco D, Korpachev V, et al. Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-naive subjects with type 2 diabetes inadequately controlled on oral antidiabetes agent. Diabetes Care. 2015;38(12):2274–2281.
  • Data on file. MannKind Corporation.
  • Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244–2253.
  • Riddle MC. Basal glucose can be controlled, but the prandial problem persists–it’s the next target! Diabetes Care. 2017;40(3):291-300.
  • Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11)3411-3417.
  • Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6(4):773-779.
img
TYPE2

Would you like to review

jason’s patient profile?

Yes, pleaseNo, thank you
img
img
TYPE1

Would you like to review

SARAH’s patient profile?

Yes, pleaseNo, thank you
img